NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Earnings Presentation

Q2 FY 22

BSE CODE : 524558 | NSE SYMBOL : NEULANDLAB | BLOOMBERG: NLL:IN | REUTERS: NEUL.NS

Safe Harbour

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Table of Contents

Q2 & H1 FY-22 HIGHLIGHTS

Management Speak

SUCHETH DAVULURI

"Our GDS business delivered growth led by the specialty segment. We believe that our sustainable operations amid these uncertain times demonstrates our execution capabilities. We are confident that our differentiated strategy of delivering differentiated products to our customers is a competitive advantage which will maximize value for all our stakeholders."

SAHARSH DAVULURI

"Our teams are working closely together to ensure smooth execution of CMS projects. We are happy to see this reflected in the increase in revenues from Development projects. We look forward to commercializing these projects in the future."

Key Highlights

Q2 FY22

Business Highlights

- In Prime API, Mirtazapine, Labetalol & Levofloxacin performed well even as there was a decrease in revenues
- Specialty had a high growth quarter with revenues coming from development revenues for Paliperidone Palmitate apart from Dorzolamide & Donepezil
- CMS revenues driven by development products close to commercialization over the next few quarters

Financial Highlights

- Total income was Rs. 258.1 crore in Q2FY22, an increase of 6.7%
- EBITDA margin decreased by 40 bps from 17.1% to **16.7%** in Q2FY22 due to
  - Increase in input prices & shipping costs
- PAT decreased by 4.7% to Rs. 20.3 crores on account of
  - Higher depreciation led by Unit 3 commercialization

Key Highlights

H1 FY22

Business Highlights

- Growth from development projects was offset by Inventory destocking at customers' end
- Unit 3 ramping up driving business volumes
- Increased headcount to account for higher business volumes in coming quarters

Financial Highlights

- Total income was Rs. 461.1 crore in H1FY22, an increase of 2.9%
- EBITDA margin decreased by 160 bps from 16.9% to **15.3%** in H1FY22 due to
  - Increase in raw material prices
  - Upfront expense on certain projects
- PAT decreased by 20.4% to Rs. 29.0 crores on account of
  - Higher depreciation led by Unit 3 commercialization

Profit & Loss Snapshot (Standalone)

Particulars (Rs. Cr)	Q2FY22	Q1FY22	QoQ (%)	Q2FY21	YoY (%)	H1FY22	H1FY21	YoY (%)
Total Income	**258.1**	202.9	*27.2%*	242.0	6.7%	461.1	448.1	2.9%
EBITDA	**43.1**	27.7	*55.8%*	41.4	4.1%	70.7	75.8	(6.7)%
EBITDA Margin	**16.7%**	13.6%	*310 bps*	17.1%	*(40) Bps*	*15.3%*	*16.9%*	*(160) Bps*
Profit Before Tax	**27.5**	12.0	*129.7%*	28.6	*(3.7)%*	*39.5*	*48.8*	*(19.0)%*
Profit Before Tax Margin	**10.7%**	*5.9%*	*480 bps*	11.8%	*(110) Bps*	*8.6%*	*10.9%*	*(230) Bps*
Profit After Tax	**20.3**	8.6	*135.1%*	21.3	*(4.7)%*	*29.0*	*36.4*	*(20.4)%*
Profit After Tax Margin	**7.9%**	4.3%	*360 bps*	8.8%	*(90) Bps*	*6.3%*	*8.1%*	*(180) Bps*
Earnings Per Share (Rs.)	**15.8**	*6.7*	*135.1%*	16.6	*(4.7)%*	*22.6*	*28.4*	*(20.4)%*

Financials (Standalone)

Revenue (Rs. Cr)



EBITDA (Rs. Cr) and EBITDA Margin (%)



EPS (Rs)



PAT (Rs. Cr)



Key Operating Metrics

YoY Analysis



Quarter on Quarter Movement



Business Salience (Overall Company)

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

PRODUCT

YoY Analysis



QoQ Movement



TOP 10
TOP 5
% of Total revenue

CUSTOMER

YoY Analysis



QoQ Movement



Business Salience (Prime)



TOP 10
TOP 5
(of Prime revenue)

PRODUCT



CUSTOMER



★ % represents Niche / Speciality % from Overall revenue for respective Quarter / YTD

Business Salience (Niche/Speciality)



NEULAND
WHERE OPPORTUNITY BECOMES REALITY

PRODUCT



TOP 10
TOP 5
(of Niche/Speciality Revenue)

CUSTOMER



★ % represents Niche / Speciality % from Overall revenue for respective Quarter / YTD

Business Salience (CMS)

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

★



PRODUCT



TOP 10
TOP 5
(of CMS revenue)

CUSTOMER



★ % represents CMS % from Overall revenue for respective Quarter / YTD

Key Operating Metrics – CMS Revenue Split

Rs. In Cr

Commercial Development

YoY Analysis



Quarter on Quarter Movement



Number of Active CMS Projects

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Q2 FY22	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	15	3	8	4	10	7	47
Intermediate	7	5	2	0	8	11	33
Grand Total	22	8	10	4	18	18	80

Q2 FY21	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	14	4	6	3	10	6	43
Intermediate	7	4	2	5	8	9	35
Grand Total	21	8	8	8	18	15	78

Q2 FY20	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	11	4	6	6	4	6	37
Intermediate	1	3	1	5	11	10	31
Grand Total	12	7	7	11	15	16	68

Q2 FY19	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	7	2	1	4	6	5	25
Intermediate	1	2		8	3	7	21
Grand Total	8	4	1	12	9	12	46

BUSINESS OVERVIEW

Our Journey – Key Milestones

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Laying Strong Foundation 1984 - 2003

Deepening our Capabilities 2004 - 2012

Increased Sustainable Growth 2013 -Today



Multiple audits passed with no failures

Generic Drug Substance (GDS)

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

We started as a Prime API manufacturer…

Capability

- ✓ 3 US FDA and EU GMP compliant manufacturing facilities
- ✓ Collective capacity: ~860 KL

Business Approach

- ✓ Work on molecules either with a business leadership approach or partnership with client
- ✓ Ensure uninterrupted supply with quality commitment

Strategy Forward

- ✓ Maintain leadership position in key molecules
- ✓ Work on process optimization to improve yields, productivity and thus margins

..Added Speciality molecules for complex products..

Capability

- ✓ High end complex chemistry capabilities
- ✓ Backend support by R&D department
- ✓ Experience of hurdle free scale up

Business Approach

- ✓ Work with leading companies and help them to meet their technical requirements while being competitive

Strategy Forward

- ✓ Focus on niche APIs with complex chemistry
- ✓ File IP for non infringing processes

Robust manufacturing base placed on the foundation of quality and pureplay API commitment

On path to being a preferred partner in CMS..

NEULAND
WHERE OPPORTUNITY BECOMES REALITY



Services

- ✓ Manufacturing API to customer specifications
- ✓ Designing and developing manufacturing processes
- ✓ Process optimization for competitiveness
- ✓ Complete CMC partner for the API
- ✓ Patent protection for processes

Business Approach

- ✓ Local presence in US and Japan with technical as well as commercial employees
- ✓ Consultative approach on customer relationships
- ✓ Business targeted on Neuland's technology capabilities and perceived customer needs leading to increased traction

Strategy Forward

- ✓ Add depth in technical capabilities
- ✓ Investment in QBD labs, process engineering and foray into new areas of customer solutions
- ✓ Work effectively on customer relationships and leverage on portfolio expansion
- ✓ Targeting molecules in the later stages of the clinical cycle

Create a sustainable CMS business that is driven by technology and strong customer relationships



CAPABILITIES

Scaled up Manufacturing Facilities over the years

	UNIT 1 BONTHAPALLY	UNIT 2 PASHAMYLARAM	UNIT 3 GADDAPOTHARAM
	233 KL	356 KL	271 KL
Year of Establishment	**1986**	**1994**	**2017**
Key Products	Mirtazapine, Sotalol HCL, Levetiracetam, Levofloxacin, Salmeterol, Salbutamol, NCE APIs, Peptide APIs, Vitamin D2 analogues	Ciprofloxacin HCL, Entacapone, NCE APIs, Intermediates & RSMs	Products including Key Intermediates
Regulatory	USFDA, EDQM, CFDA, PMDA	USFDA, EDQM, PMDA, ANVISA	Inspected by USFDA as an Advanced Intermediates site in 2015

Adding capacities for business growth and strategic backward integration

Backed up by sound R&D capabilities

Neuland's R&D facility had been inspected by USDFA in February 2016 without any observations

Infrastructure

- 15 Development Labs with space for expansion
- 60 Fume hoods
- Analytical Labs
- Dedicated kilo Lab for Scale up
- Dedicated Labs for Peptides
- Separate facility for D2 analogues

Significant R&D Achievements

- Several NCE APIs added in NDA or commercial stage drugs
- Support for multiple APIs each year in Phase 2 and Phase 3 clinical candidates
- Generic API business -

✓ 900+ DMFs filed

✓ 300+ API processes developed

✓ 204+ patents filed. Received USPTO patent for improved process synthesis of Paliperidone Palmitate

New capabilities built

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Research Capabilities

FBRM

Particle size check for polymorph achievement

PEPTIDE LAB

9800 sq. ft. new lab with additional 7 hoods for 25 chemists

POLY BLOCK REACTORS

For solubility/ crystallisation study, carrying out multiple reactions

LABORATORY REACTORS

Enhanced ability to perform reactions in a wide range of -90-200 degrees

HAZARDOUS & WET LABORATORY

Dedicated area for hazardous chemical management and wet lab expansion

PID LABORATORY, UNIT-III

To address product quality issues, impurities synthesis, cost reduction.

PID LABORATORY, B-S, UNIT-I

Expansion with 3 fume hoods along with space for 2 more laboratories.

HEATING & COOLING SYSTEMS

For DOE studies and projects

Regulatory Filings Across Geographies

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

57
DMFs with USFDA

Health Canada
30
Filings with Health Canada

10
Japanese DMF filed

NMPA 国家药品监督管理局 National Medical Products Administration
20
China DMF filed

FDA Korea Food & Drug Administration 식품의약품안전청
19
filings with KFDA Korea

Australian Government Department of Health Therapeutic Goods Administration
22
filings with TGA


220
ROW filings including Turkey, Mexico, Brazil etc

~495
EUDMF filings across Germany, France, Poland, Italy etc

edqm
European Directorate for the Quality of Medicines & HealthCare | Direction européenne de la qualité du médicament & soins de santé

COUNCIL OF EUROPE
CONSEIL DE L'EUROPE

27
CEPs Received for different products

900+
Filings till date

* The numbers on this slide reflect the number of filings, the number of active filings could vary as geographic filings are merged and the product portfolio is optimized

Global Presence



% Refers to Q1 FY22 Sales by End market

Neuland Today: Snapshot

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Legacy

Expertise:
37+ years backed by robust quality systems, regulatory & compliance framework

---

Generic Drugs Substance(GDS) & Custom Manufacturing Solutions(CMS)

Scale



3 Mfg. Facilities: Regulatory approved with 860 KL capacity

R&D: US FDA approved with best in class infrastructure

Capability

Product/ Projects portfolio: 100+ APIs across therapeutic categories

---

Regulatory filings 898+

Team: 1400+ incl. ~300 R&D scientists

Reach

Presence 80+ countries

Export revenues 75%

Regulated markets revenue 93%

FINANCIALS

Continuous Growth…

Rs. In Cr



	FY19	FY20	FY21	H1FY22
Sales	670	767	953	461
EBITDA	61	105	163	71
Net Profit	16	16 *	80	29

FINANCIAL PERFORMANCE HIGHLIGHTS

- Revenue CAGR of 19.2% for FY 19-21 led by growth in all 3 businesses
- EBITDA growth of 62.8% CAGR in FY 19-21 due to balanced contribution from both GDS and CMS business
- Shift to CMS and Speciality in overall revenue mix along with resource efficiency steps accelerated profitability

* This was after a one-time tax charge of Rs. 23.2 Cr in Q4FY20 that the Company chose to exercise under Section 115BAA of the IT act

Stable Balance Sheet..

Particulars (Rs. Cr)	Mar-19	Mar-20	Mar-21	Sep-21
Shareholders ' funds	696	706	782	803
Net Debt	194	214	152	184
Investments	8	8	7	4
Tangible Assets	367	391	438	476
Intangible Assets (Excluding Goodwill)	2	2	3	3
Working Capital	233	289	309	348

Current Ratio (x)



ROCE (%)



Fixed Asset Turnover (x)



Debt to Equity (x)



Macroeconomic factors influencing Neuland

FACTORS	IMPACT	NEULAND RESPONSE
Government regulation: approvals, audits	▪ Consistent regulatory audits ▪ Increased scrutiny prior to drug approvals	▪ Successfully cleared all USFDA audits since inception ▪ Consistent record of new drug approvals
Environmental audits	Government led impact monitoring	All environmental regulations complied
Crude oil prices	Solvent price volatility	Green chemistry investing for efficient solvent use
COVID 19 impact	▪ Increased logistics costs ▪ IPA availability and pricing fluctuations ▪ Employee and operational repercussions	▪ Tactical scheduling for channel mix optimization ▪ Qualifying new IPA manufacturers with increased capacity ▪ Added contingent personnel and pro-active monitoring for early warnings
Human Capital	Competition for talent	▪ Retraining via strong L & D plan ▪ Leadership pipeline development across levels
Western Government policies on localisation	Sales reduction	▪ Close partnership with customers along with focus on Specialty molecules ▪ Close monitoring of country specific government regulations

OUTLOOK

..Laying Foundation for our Growth Strategy

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

CREATE AN ORGANIZATION THAT RESULTS IN VALUE FOR ALL STAKEHOLDERS

BUSINESS

Extend capabilities to organically build a sustainable GDS and CMS business

CHEMISTRY

Deploy advanced chemistry skills to add differentiated products to its portfolio

QUALITY

Develop techniques like QBD to stay ahead of the curve & set precedents for "no quality compromise"



SCALE

Invest into capacity to augment sales and accelerate business growth

RELATIONSHIPS

Leverage on Long – standing relationships with leading generic and innovator companies

FINANCIALS

Re-aligning revenue portfolio for a profitable growth

Contact Us

NEULAND
WHERE OPPORTUNITY BECOMES REALITY

For over 37 Years, Neuland Laboratories Ltd. (BSE:524558, NSE: NEULANDLAB) has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries.

Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (57 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For further information contact

IR Desk
Neuland Labs
+91 40 6761 1600
ir@Neulandlabs.com

Diwakar Pingle
Christensen IR
+91 22 4215 0210
dpingle@christensenir.com

NEULAND

WHERE OPPORTUNITY BECOMES REALITY

Thank You